Clinical trials: Maculopathy
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Central Retinal Vein Occlusion
Bevacizumab for Central Retinal Vein Occlusion Study
Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity.
- Trial name
- NCT00906685
- Testing
- bevacizumab
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Anders Kvanta
Age Related Macular Degeneration, Intermediate AMD
A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
This is a multicentre retrospective and prospective cohort study with the goal to develop a well-characterised multimodal image database of eyes with intermediate AMD with and without early atrophy. The main objectives are: 1.
- Conditions
- Age Related Macular Degeneration, Intermediate AMD, Atrophy, Prediction
- Trial name
- INTERCEPT-AMD (NCT05698316)
- Testing
- Collection of both retrospective and prospective data collection in 3 visits.
- Where
- 25 sites in France, Germany and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Macular Degeneration, Low Vision
The Effect of Duration Between Sessions on Microperimetric Biofeedback Training in Patients With Maculopathies
Patients who develop macular diseases have several clinical complications,such as central vision loss, the central scotoma of the visual field, the decrease of reading speed and fixation stability.
- Conditions
- Macular Degeneration, Low Vision, Stargardt Disease
- Trial name
- NCT05904444
- Testing
- microperimetric biofeedback training
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Aier Eye Hospital, Guangzhou
Macular Edema, Retinal Vein Occlusion
Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients with Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection
Retinal vein occlusion (RVO) is one of the most common causes of vision loss due to retinal vascular disease. Incidence of RVO has been raised in the last years due to increased coexisting systemic vascular risk factors as…
- Trial name
- NCT05003258
- Testing
- Intravitreal injection of Dexamethasone implant
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Assiut University
Wet AMD
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
- Trial name
- NCT01310686
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Coast Retina Medical Group, Inc.
Choroiditis, Iridocyclitis
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
This study offers evaluation and treatment for patients with inflammatory eye diseases, such as uveitis. The protocol is not designed to test new treatments; rather, patients will receive current standard of care treatments.
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Trial name
- NCT00006188
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Eye Institute (NEI)
Retinal Disease, AMD
Cell Collection to Study Eye Diseases
Background: Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye.
- Conditions
- Retinal Disease, AMD, Retinal Degeneration, Retinitis Pigmentosa
- Trial name
- NCT01432847
- Where
- United States
- Volunteers
- 930 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
STGD1, Stargardt Disease 1
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
- Trial name
- DRAGON II (NCT06388083)
- Testing
- Tinlarebant
- Where
- 18 sites in United States, Japan and 1 more
- Volunteers
- 60 people
- Sponsor
- Belite Bio, Inc
Age-Related Macular Degeneration
Patient-centred Smartphone AI for Protecting Vision in Macular Disease
Macular disease is the leading cause of blindness in the UK and age-related macular degeneration must undergo monitoring to determine if an injection into the eye is required that month [required in 50% of visits] - these…
- Trial name
- NCT05433766
- Where
- 2 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- OKKO Health
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Stargardt Disease
This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
Stargardt disease 1 (STGD1) is the most prevalent form of juvenile macular degeneration. It is caused by a rare, inherited autosomal recessive trait, leading to severe and irreversible blindness by the first or second decade of…
- Trial name
- NCT05266014
- Testing
- tinlarebant
- Where
- 3 sites in Australia, Taiwan
- Volunteers
- 13 people
- Sponsor
- RBP4 Pty Ltd
Optic Disc Pit Maculopathy
Vitrectomy for Optic Disc Pit Maculopathy
The purpose of this study is to evaluate the efficacy of vitrectomy, without gas tamponade or laser photocoagulation to the margin of the optic nerve, for the treatment of macular detachment associated with optic disc pits and to…
- Trial name
- NCT01340703
- Testing
- vitrectomy without laser or gas tamponade
- Where
- Japan
- Volunteers
- 8 people
- Sponsor
- Kyorin University
Branch Retinal Vein Occlusion
Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion
The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.
- Trial name
- NCT00370266
- Testing
- Triamcinolone
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
Effects of VEGF Trap-Eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (PCV) will be evaluated.
- Trial name
- VAULT (NCT01950741)
- Testing
- aflibercept
- Where
- 8 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Pusan National University Hospital
Cystoid Macular Edema
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
To report safety and efficacy of intravitreal injection of bevacizumab in patients with cystoid macular edema secondary to cataract surgery.
- Trial name
- NCT00406172
- Testing
- Bevacizumab
- Where
- Mexico
- Sponsor
- Asociación para Evitar la Ceguera en México
Age-Related Macular Degeneration
ForeseeHome NRich Registry
This registry will compare functional and structural data of progression of Intermediate AMD (iAMD) and conversion to neovascular AMD (NV-AMD) while monitored at home with the ForeseeHome Monitoring System (FSH) and during…
- Trial name
- NCT05690880
- Testing
- Foresee Home
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Notal Vision Inc.
Stargardt Disease, Stargardt Macular Dystrophy
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye.
- Conditions
- Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy
- Trial name
- EVOLVE (NCT07425574)
- Testing
- No Intervention
- Where
- 15 sites in United States
- Volunteers
- 90 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Stargardt Disease
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.
- Trial name
- SUSTAIN (NCT06048185)
- Testing
- Gene Therapy Product-MCO-010
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Nanoscope Therapeutics Inc.